A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells

Oncogene

Volumn 34, Issue 32, 2015, Pages 4199-4210

  Thrane, S ^a   Pedersen, A M ^a   Thomsen, M B H ^a   Kirkegaard, T ^a   Rasmussen, B B ^b   Duun Henriksen, A K ^a   Laenkholm A V ^c   Bak, M ^d   Lykkesfeldt, A E ^a   Yde, C W ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c SLAGELSE HOSPITAL   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; AURORA KINASE INHIBITOR; DEUBIQUITINASE; FULVESTRANT; JNJ 7706621; PROTEIN MCL 1; TAMOXIFEN; UNCLASSIFIED DRUG; WP 1130; ANTIESTROGEN; CASPASE; CYANOACRYLATE DERIVATIVE; DEGRASYN; ESTRADIOL; ESTROGEN RECEPTOR; JNJ-7706621; MCL1 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; TUMOR MARKER;

ARTICLE; CANCER CELL; CANCER PATIENT; CELL DEATH; CELL GROWTH; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GROWTH INHIBITION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MCF 7 CELL LINE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; METABOLISM; RNA INTERFERENCE; SURVIVAL; TUMOR CELL LINE;

APOPTOSIS; AURORA KINASE A; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CYANOACRYLATES; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ESTRADIOL; ESTROGEN ANTAGONISTS; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MCF-7 CELLS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTEIN KINASE INHIBITORS; PYRIDINES; RECEPTORS, ESTROGEN; RNA INTERFERENCE; SURVIVAL ANALYSIS; TAMOXIFEN; TRIAZOLES;

EID: 84938954940     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.351     Document Type: Article

References (57)

1. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771-784.
2. Howell A, Osborne CK, Morris C, Wakeling AE. ICI 182 780 (Faslodex): development of a novel, 'pure' antiestrogen. Cancer 2000; 89: 817-825.
3. Palmieri C, Patten DK, Januszewski A, Zucchini G, Howell SJ. Breast cancer: current and future endocrine therapies. Mol Cell Endocrinol 2013; 382: 695-723.
4. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9: 631-643.
5. Nahta R, O'Regan RM. Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers. Breast Cancer Res Treat 2012; 135: 39-48.
6. Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 2008; 9: 23-28.
7. Drury SC, Detre S, Leary A, Salter J, Reis-Filho J, Barbashina V et al. Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. Endocr Relat Cancer 2011; 18: 565-577.
8. Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. Breast Cancer Res 2009; 11: R11.
9. Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV et al. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat 2009; 114: 263-275.
10. Sonne-Hansen K, Norrie IC, Emdal KB, Benjaminsen RV, Frogne T, Christiansen IJ et al. Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance. Breast Cancer Res Treat 2010; 121: 601-613.
11. Thrane S, Lykkesfeldt AE, Larsen MS, Sorensen BS, Yde CW. Estrogen receptor alpha is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. Breast Cancer Res Treat 2013; 139: 71-80.
12. Yde CW, Emdal KB, Guerra B, Lykkesfeldt AE. NFkappaB signaling is important for growth of antiestrogen resistant breast cancer cells. Breast Cancer Res Treat 2012; 135: 67-78.
13. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet 2011; 43: 27-33.
14. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 2012; 481: 389-393.
15. Howell A, Robertson J. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 1995; 345: 989-990.
16. Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003; 98: 229-238.
17. Frankel LB, Lykkesfeldt AE, Hansen JB, Stenvang J. Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells. Breast Cancer Res Treat 2007; 104: 165-179.
18. Frogne T, Jepsen JS, Larsen SS, Fog CK, Brockdorff BL, Lykkesfeldt AE. Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth. Endocr Relat Cancer 2005; 12: 599-614.
19. Leary AF, Drury S, Detre S, Pancholi S, Lykkesfeldt AE, Martin LA et al. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin Cancer Res 2010; 16: 1486-1497.
20. Bartholomeusz GA, Talpaz M, Kapuria V, Kong LY, Wang S, Estrov Z et al. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood 2007; 109: 3470-3478.
21. Sun H, Kapuria V, Peterson LF, Fang D, Bornmann WG, Bartholomeusz G et al. Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. Blood 2011; 117: 3151-3162.
22. Christensen GL, Jepsen JS, Fog CK, Christensen IJ, Lykkesfeldt AE. Sequential versus combined treatment of human breast cancer cells with antiestrogens and the vitamin D analogue EB1089 and evaluation of predictive markers for vitamin D treatment. Breast Cancer Res Treat 2004; 85: 53-63.
23. Larsen SS, Heiberg I, Lykkesfeldt AE. Anti-oestrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analogue EB1089 than parent MCF-7 cells. Br J Cancer 2001; 84: 686-690.
24. Lykkesfeldt AE, Larsen SS, Briand P. Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. Int J Cancer 1995; 61: 529-534.
25. Yde CW, Gyrd-Hansen M, Lykkesfeldt AE, Issinger OG, Stenvang J. Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death. Mol Cancer Ther 2007; 6: 1869-1876.
26. Cohen NA, Stewart ML, Gavathiotis E, Tepper JL, Bruekner SR, Koss B et al. A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival. Chemistry & biology 2012; 19: 1175-1186.
27. Emanuel S, Rugg CA, Gruninger RH, Lin R, Fuentes-Pesquera A, Connolly PJ et al. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclindependent kinases and aurora kinases. Cancer Res 2005; 65: 9038-9046.
28. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3: 46-54.
29. Hendzel MJ, Wei Y, Mancini MA, Van Hooser A, Ranalli T, Brinkley BR et al. Mitosisspecific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 1997; 106: 348-360.
30. Dar AA, Goff LW, Majid S, Berlin J, El-Rifai W. Aurora kinase inhibitors - rising stars in cancer therapeutics? Mol Cancer Ther 2010; 9: 268-278.
31. Lykkesfeldt AE, Madsen MW, Briand P. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164 384 and ICI 182 780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res 1994; 54: 1587-1595.
32. Chan SK, Hill ME, Gullick WJ. The role of the epidermal growth factor receptor in breast cancer. J Mammary Gland Biol Neoplasia 2006; 11: 3-11.
33. Hutcheson IR, Knowlden JM, Madden TA, Barrow D, Gee JM, Wakeling AE et al. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res Treat 2003; 81: 81-93.
34. Kapuria V, Peterson LF, Fang D, Bornmann WG, Talpaz M, Donato NJ. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res 2010; 70: 9265-9276.
35. Teixeira C, Reed JC, Pratt MA. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 1995; 55: 3902-3907.
36. Thomas LW, Lam C, Edwards SW. Mcl-1; the molecular regulation of protein function. FEBS Lett 2010; 584: 2981-2989.
37. Wang JM, Chao JR, Chen W, Kuo ML, Yen JJ, Yang-Yen HF. The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol Cell Biol 1999; 19: 6195-6206.
38. Booy EP, Henson ES, Gibson SB. Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer. Oncogene 2011; 30: 2367-2378.
39. Henson ES, Hu X, Gibson SB. Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression. Clin Cancer Res 2006; 12: 845-853.
40. Ding Q, He X, Xia W, Hsu JM, Chen CT, Li LY et al. Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer. Cancer Res 2007; 67: 4564-4571.
41. Vogler M, Dinsdale D, Dyer MJ, Cohen GM. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 2009; 16: 360-367.
42. Kallio MJ, McCleland ML, Stukenberg PT, Gorbsky GJ. Inhibition of aurora B kinase blocks chromosome segregation, overrides the spindle checkpoint, and perturbs microtubule dynamics in mitosis. Curr Biol 2002; 12: 900-905.
43. Hirota T, Kunitoku N, Sasayama T, Marumoto T, Zhang D, Nitta M et al. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 2003; 114: 585-598.
44. Crosio C, Fimia GM, Loury R, Kimura M, Okano Y, Zhou H et al. Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol Cell Biol 2002; 22: 874-885.
45. Goldenson B, Crispino JD. The aurora kinases in cell cycle and leukemia. Oncogene 2015; 34: 537-545.
46. Pancholi S, Lykkesfeldt AE, Hilmi C, Banerjee S, Leary A, Drury S et al. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifenresistant MCF-7 cells leading to the activation of AKT and RPS6KA2. Endocr Relat Cancer 2008; 15: 985-1002.
47. Le Gouill S, Podar K, Harousseau JL, Anderson KC. Mcl-1 regulation and its role in multiple myeloma. Cell cycle 2004; 3: 1259-1262.
48. Ali HR, Dawson SJ, Blows FM, Provenzano E, Pharoah PD, Caldas C. Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer. Br J Cancer 2012; 106: 1798-1806.
49. Zheng XQ, Guo JP, Yang H, Kanai M, He LL, Li YY et al. Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERa in breast cancer. Oncogene 2014; 33: 4985-4996.
50. Siggelkow W, Boehm D, Gebhard S, Battista M, Sicking I, Lebrecht A et al. Expression of aurora kinase A is associated with metastasis-free survival in nodenegative breast cancer patients. BMC Cancer 2012; 12: 562.
51. Briand P, Lykkesfeldt AE. Effect of estrogen and antiestrogen on the human breast cancer cell line MCF-7 adapted to growth at low serum concentration. Cancer Res 1984; 44: 1114-1119.
52. Lundholt BK, Briand P, Lykkesfeldt AE. Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways. Breast Cancer Res Treat 2001; 67: 199-214.
53. Zhang H, Guttikonda S, Roberts L, Uziel T, Semizarov D, Elmore SW et al. Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines. Oncogene 2011; 30: 1963-1968.
54. Yde CW, Olsen BB, Meek D, Watanabe N, Guerra B. The regulatory beta-subunit of protein kinase CK2 regulates cell-cycle progression at the onset of mitosis. Oncogene 2008; 27: 4986-4997.
55. Moller S, Jensen MB, Ejlertsen B, Bjerre KD, Larsen M, Hansen HB et al. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol 2008; 47: 506-524.
56. Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Moller S, Ejlertsen B, Mouridsen HT. Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays. J Clin Pathol 2007; 60: 397-404.
57. Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Moller S, Ejlertsen B, Mouridsen HT et al. activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer. Acta Oncol 2009; 48: 522-531.